Securities code: 300639 securities abbreviation: Guangdong Hybribio Biotech Co.Ltd(300639) Announcement No.: 2022-003 Guangdong Hybribio Biotech Co.Ltd(300639)
Announcement on the selection of investment partners of the holding subsidiary winning the bid for the project of building a third-party medical laboratory in Nanhai District, Foshan City
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Recently, Guangdong Hybribio Biotech Co.Ltd(300639) (hereinafter referred to as “the company”) holding subsidiary Guangzhou Kaipu Medical Laboratory Development Co., Ltd. (hereinafter referred to as “Kaipu medical laboratory”) won the bid for the project selected by the investment partner of the project of building a third-party medical laboratory in Nanhai District, Foshan City, and received the letter of acceptance issued by the bidding agency Guangdong electromechanical equipment bidding Co., Ltd. Details are as follows:
1、 Basic information of the project
1. Project name: selection of investment partners for the construction of third-party Medical Laboratory
2. Project No.: m4400000707012215001
3. Tenderee: Guangdong Nanhai Safety Technology Investment Holding Co., Ltd
4. Bid winner: Guangzhou Kaipu Medical Laboratory Development Co., Ltd
5. Annual return on investment after winning the bid: 11.20%
6. Project content: Nanhai District, Foshan City plans to build an independent for-profit third-party testing institution through investment promotion of state-owned enterprises under the District State owned assets supervision and Administration Bureau and cooperation with third-party testing institutions. The institution is required to have a testing capacity of 100000 tubes / day, and undertake the storage task of equipment and consumables required by Nanhai District People’s hospital to improve the testing capacity of 100000 tubes / day. The institution is an urban nucleic acid testing base of “combination of peacetime and wartime”. In peacetime, the testing capacity is maintained at 10000 tubes / day respectively. In wartime, it is promoted to a total of no less than 200000 tubes / day through rapid deployment of personnel, equipment and materials, and the testing capacity of no less than 2 million people / day is achieved by 10 in 1 mixed mining, which can basically meet the needs of all staff screening in Nanhai District, Foshan City in one day.
2、 Impact on the company and risk tips
The company has received the letter of acceptance and has not signed a formal written contract with Guangdong Nanhai Safety Technology Investment Holding Co., Ltd. the content of the contract is still uncertain, and the specific content shall be subject to the final signed contract. The company will sign a written contract with Guangdong Nanhai Safety Technology Investment Holding Co., Ltd. in accordance with the requirements of the letter of acceptance, the civil code and other relevant laws and regulations, as well as the matters determined in the bidding documents and the commitments in the bidding documents. According to the bidding documents, if the above contract can be formally signed and successfully implemented, after the establishment of the third-party testing institution to be invested and constructed, Kemp medical testing will hold 60% of the equity of the third-party testing institution, which will be included in the scope of the company’s consolidated statements without affecting the independence of the company’s business and operation. The proposed cooperation contract constitutes an external investment, which is in line with the company’s overall development strategic plan. The company will perform the corresponding approval procedures according to the specific investment amount, and strictly comply with the relevant provisions such as the Listing Rules of GEM stocks of Shenzhen Stock Exchange, the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies, Fulfill the corresponding information disclosure obligations, please pay attention to the investment risks.
3、 Documents for future reference
1. Notification of award.
2. Bid winning announcement on the selection of investment partners for the construction of third-party medical laboratory project.
It is hereby announced.
Guangdong Hybribio Biotech Co.Ltd(300639) board of directors
January 12, 2002
